Table 9.
Poxvirus genes deleted in poxvirus-based vaccine candidates against infectious diseases that enhance the vector immunogenicity.
| Pox Strain | Target Pathogen or Disease | Heterologous Antigen | Poxvirus Deleted Gene | Gene Function | Status | References |
|---|---|---|---|---|---|---|
| MVA | HIV/AIDS | HIV-1 Env, Gag-Pol-Nef (clade B) |
A41L/B16R |
A41L: Secreted chemokine-binding protein B16R: Secreted interleukin-1β binding protein |
preclinical | [528] |
| HIV-1 Env, Gag-Pol-Nef (clade B) |
C6L | IRF3 inhibitor | preclinical | [527,529] | ||
| HIV-1 Env, Gag-Pol-Nef (clade B) |
C6L/K7R |
C6L: IRF3 inhibitor K7R: NF-кB/IRF3 inhibitor |
preclinical | [527] | ||
| HIV-1 Env, Gag-Pol-Nef (clade B) |
N2L | IRF3 inhibitor | preclinical | [537] | ||
| HIV-1 Env, Gag-Pol-Nef (clade C) |
F1L | Anti-apoptotic protein | preclinical | [532] | ||
| HIV-1 Env, Gag-Pol-Nef (clade C) |
C12L | IL-18 binding protein | preclinical | [516] | ||
| HIV-1 Env, Gag (clade C) |
C12L/A46R/B7R/B16R |
C12L: IL-18 binding protein A46R: Inhibitor of TLR signaling B7R: Putative chemokine-binding protein B16R: Secreted interleukin-1β binding protein |
preclinical | [533] | ||
| NYVAC | HIV/AIDS | HIV-1 Env, Gag-Pol-Nef (clade C) |
B8R | Secreted IFNγ binding protein | preclinical | [530] |
| HIV-1 Env, Gag-Pol-Nef (clade C) |
B19R | Type I IFN binding protein | preclinical | [530] | ||
| HIV-1 Env, Gag-Pol-Nef (clade C) |
A46R | Inhibitor of TLR signaling | preclinical | [531] | ||
| MVA | Chikungunya | C-E1-E2-6K-E3 | C6L/K7R/A46R |
C6L: IRF3 inhibitor K7R: NF-кB/IRF3 inhibitor A46R: Inhibitor of TLR signaling |
preclinical | [327] |
| MVA | Smallpox | - | A35R | Inhibitor of MHC class II antigen presentation | preclinical | [517] |
| FWPV | AIV | HA | ORF73 or ORF214 | Suggested interleukin-18 binding proteins | preclinical | [541] |
Abbreviations: AIV: Avian influenza virus; HA: Hemagglutinin.